Please login to the form below

Not currently logged in
Email:
Password:

Dr Irina Antonijevic joins vasopharm

Becomes chief medical officer of the cerebrovascular specialist

vasopharm Dr Irina AntonijevicWürzburg, Germany-based vasopharm has appointed Dr Irina Antonijevic to the newly-created position of chief medical officer.

In this role, Dr Antonijevic will be responsible for advancing the clinical development of the cerebrovascular specialist's lead orphan drug candidate, VAS203.

She brings over 15 years of global drug development experience in neuroscience to vasopharm, having held positions at Schering's German operations and Lundbeck Research in the US.

Most recently, Dr Antonijevic served as global head of early development in neurology, multiple sclerosis and ophthalmology at Sanofi Genzyme in the US.

Dr Andrew Clark, chairman of the board at vasopharm, said: “We are delighted that Dr Antonijevic will be joining the team at vasopharm.

“Not only will we benefit from her clinical capabilities in our ongoing pivotal study of VAS203 in TBI, but also from her extensive expertise in pre-clinical development as we examine the compound in additional indications.

“We see her commitment to vasopharm as a substantial endorsement of the potential of the programmes underway at the company.”

25th November 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics